Therapeutic Solutions International, Inc. Announces the
Appointment of Vijay Mahant, Ph.D., M.S. to the TSI Scientific
Advisory Board
Oceanside, CA -- October 26, 2015 -- InvestorsHub NewsWire --
Therapeutics Solutions International, Inc., (OTC
Markets:TSOI) announced today that Vijay Mahant, Ph.D., M.S.
has been appointed to our Scientific Advisory Board.
Dr. Mahant has been involved in Research and Development in the
medical industry for close to 30 years. Working in the FDA
regulated medical industry, he has headed R&D activities for
several bio-medical companies as well as being the founder, CEO
& Chairman of MediLite, Inc. Dr. Mahant has specialized in the
areas of assay development, has numerous patents to his credit and
has published extensively.
We are honored indeed to welcome Dr. Mahant to our Scientific
Advisory Board who joins the team of Dr. Michael G. Agadjanyan, Dr.
Santosh Kesari, Dr. Harry M. Lander and Dr. Francesco M. Marincola
who we previously announced. The Advisory Board will review,
evaluate and report to the company Board of Directors regarding
strategy, plans and goals, as well as progress and performance, of
the Companys development programs and research activities. said
Timothy Dixon, President and CEO.
Dr. Mahant received his B.S. in Biochemistry from the University
of Salford, UK; a M.S. in Medicinal Chemistry and a Ph.D. in
Medical Biochemistry from Lougborough University of Technology,
UK.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION